AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

AstraZeneca (GB:AZN) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

The case involves fabricating genetic testing data to boost sales of AZ’s EGFR lung cancer med Tagrisso. “[W]e take the ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

The CHMP positive opinions for the approval and the Type II extension of the indication are supported by data from the Phase III MARIPOSA study which evaluated Rybrevant in combination with Lazcluze ...

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...